Bendazac L-lysine

Bendazac L-lysine (CAS No.: 81919-14-4) is a small molecule research compound classified as a lysine salt form of bendazac and is broadly studied in ophthalmic and inflammation related pharmacology as a synthetic non steroidal anti inflammatory associated scaffold with lens protein protective properties, where current preclinical evidence is interpreted to support a primary research category of protein homeostasis and oxidative or inflammatory stress modulation rather than target selective enzyme inhibition; in biomedical research settings it is commonly used as a tool compound to investigate mechanisms of lens protein denaturation resistance, maintenance of crystallin structural integrity, and attenuation of stress associated protein aggregation in ocular models, while in broader discovery workflows it may also be profiled in phenotypic anti inflammatory panels and comparative studies of cytoprotection under chemically induced damage paradigms; although a single universally accepted molecular target and canonical signaling axis have not been conclusively established, reported mechanistic hypotheses generally involve modulation of protein stability networks and suppression of downstream stress responses linked to inflammatory mediator production, and therefore pathway level interpretation typically focuses on redox imbalance associated damage processes and inflammation connected signaling contexts rather than a definitive receptor specific mechanism; quantitative in vitro potency metrics such as standardized IC50 or EC50 values are not consistently reported across publicly summarized sources for this specific molecule, so activity is usually described qualitatively or in broad concentration intervals that are often in the micromolar domain in exploratory assays, with exact effective ranges varying by model system, insult type, and endpoint definition; typical research applications include use in lens epithelial or lens protein based in vitro assays, ex vivo ocular tissue paradigms, and selected animal studies examining protein opacification related phenotypes or inflammation associated readouts, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, making Bendazac L-lysine a relevant reference molecule for non clinical mechanistic research and early stage screening programs focused on ocular protein protection and stress response biology.